Erceflora and Bacillus clausii Content
Yes, Erceflora is a commercial probiotic product that contains Bacillus clausii (now reclassified as Alkalihalobacillus clausii) spores. This spore-forming probiotic is marketed under various brand names globally, including Erceflora in some regions, and typically contains multiple strains of B. clausii 1, 2.
Product Composition and Quality Considerations
The specific strain composition and quality of B. clausii products varies significantly between manufacturers, which is a critical clinical consideration. Research examining commercial B. clausii products reveals important quality control issues:
Only certain brands consistently match their label claims for both bacterial count and species identification. Studies found that products like Enterogermina® demonstrated homogenous B. clausii populations matching label specifications, while other commercial preparations showed discrepancies 1, 2.
Quality control problems are common in the B. clausii probiotic market. Analysis of multiple commercial products revealed that some contained incorrect bacterial species, contaminant organisms (including potentially pathogenic Bacillus cereus), or failed to meet labeled spore counts 2, 3.
The typical labeled dose is 2 × 10⁹ CFU per 5 mL for oral suspension formulations, though actual viable counts may differ from label claims in lower-quality products 2.
Clinical Evidence and Guidelines
Current AGA guidelines do not specifically recommend B. clausii for any gastrointestinal indication, as the available evidence focuses on other probiotic strains 4. The guideline recommendations include:
For acute gastroenteritis in children: The AGA suggests against the use of probiotics generally (conditional recommendation, moderate evidence) 4.
For antibiotic-associated diarrhea prevention: The AGA recommends specific strains including Saccharomyces boulardii and certain Lactobacillus combinations, but B. clausii is not among the recommended strains 4.
For other gastrointestinal conditions (IBS, IBD, C. difficile treatment): Probiotics are recommended only in clinical trial contexts, with no specific role for B. clausii 4.
Recent Clinical Data on B. clausii
Despite the lack of guideline support, emerging evidence suggests potential benefits:
A 2025 meta-analysis found B. clausii (O/C, N/R, SIN, T strains) effective for treating acute gastroenteritis in children, reducing diarrhea duration by 0.6 Hedge's g, stool frequency by 0.34 Hedge's g, and hospital stay by 0.27 Hedge's g 5.
For antibiotic-associated diarrhea prevention, B. clausii at 4 × 10⁹ CFU/day for children and 6 × 10⁹ CFU/day for adults showed significant reduction in AAD incidence and gastrointestinal symptoms 6.
Safety Concerns
While generally considered safe, B. clausii can cause serious infections in vulnerable patients:
A 2025 case report documented Alkalihalobacillus clausii bacteremia causing septic shock in an 87-year-old man treated with the probiotic for acute diarrhea, requiring intensive care and daptomycin therapy 7.
This mirrors broader probiotic safety concerns highlighted in AGA guidelines, particularly regarding potential translocation in immunocompromised or critically ill patients 8.
Clinical Bottom Line
If prescribing Erceflora or any B. clausii product, verify the specific strain composition and choose products with documented quality control (such as Enterogermina®, which has the most consistent evidence for containing authentic B. clausii strains) 1, 2. However, for evidence-based probiotic therapy following current guidelines, consider the AGA-recommended strains instead (S. boulardii, specific Lactobacillus and Bifidobacterium combinations) for conditions where probiotics have proven benefit 4. Avoid B. clausii in immunocompromised, critically ill, or elderly frail patients given the documented risk of invasive infection 7.